Nicholas Thomson, MD
Hematology & Oncology · American Fork, UTNPI 1891106936
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,848 of the $21,249 with a category attached, or 60.5%. 60 manufacturers reported payments, led by Daiichi Sankyo Inc. at 31.7% of the total. Reporting peaked in 2024 at $9,101 and has fallen 58.7% since, to $3,762 in 2025.
Across 717 payments — averaging $29.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$7K
- Novartis$2K
- Incyte Corporation$1K
- Pfizer$1K
- AstraZeneca$980
- Merck$719
- plus $9K from 54 others
What the payments were for
- Consulting fees$7,10433%
- Food & beverage$12,84860%
- Education$7984%
- Other$4992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JAKAFI$860
How this compares
$21,249 in reported general payments places this provider in the 75th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 44 | $682,568 |
| RevlimidLenalidomide | 40 | $682,057 |
| BrukinsaZanubrutinib | 39 | $464,102 |
| CabometyxCabozantinib S-Malate | 11 | $282,848 |
| Lenalidomide | 23 | $276,260 |
| Kisqali Femara Co-PackRibociclib Succinate/Letrozole | 19 | $264,499 |
| JakafiRuxolitinib Phosphate | 11 | $178,219 |
| KisqaliRibociclib Succinate | 13 | $176,068 |
| InqoviDecitabine/Cedazuridine | 15 | $122,806 |
| EliquisApixaban | 48 | $41,889 |
| XareltoRivaroxaban | 13 | $14,272 |
| Anastrozole | 98 | $2,603 |
| Exemestane | 13 | $1,474 |
| Letrozole | 71 | $1,248 |
| Tamoxifen Citrate | 62 | $1,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $517 | $682,56844 claims |
| Bristol Myers SquibbRevlimid | $298 | $682,05740 claims |
| Exelixis Inc.Cabometyx | $49 | $282,84811 claims |
| Incyte CorporationJakafi | $1,279 | $178,21911 claims |
| NovartisKisqali | $1,515 | $176,06813 claims |
| Taiho Oncology, Inc.Inqovi | $81 | $122,80615 claims |
| PfizerEliquis | $1,004 | $41,88948 claims |
| Johnson & JohnsonXarelto | $407 | $14,27213 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $20748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in American Fork
- Douglas SborovSalt Lake City$473K
- Belisario ArangoOgden$374K
- Mark LewisMurray$319K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Terence RhodesCedar City$147K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.